- Home
- CISS vs ALZN Comparison
CISS vs ALZN Comparison
Compare CISS & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- ALZN
- Stock Information
- Founded
- CISS 2022
- ALZN 2016
- Country
- CISS Greece
- ALZN United States
- Employees
- CISS N/A
- ALZN N/A
- Industry
- CISS Marine Transportation
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- CISS Consumer Discretionary
- ALZN Health Care
- Exchange
- CISS Nasdaq
- ALZN Nasdaq
- Market Cap
- CISS 2.8M
- ALZN 2.3M
- IPO Year
- CISS N/A
- ALZN 2021
- Fundamental
- Price
- CISS $3.62
- ALZN $3.29
- Analyst Decision
- CISS
- ALZN Strong Buy
- Analyst Count
- CISS 0
- ALZN 1
- Target Price
- CISS N/A
- ALZN $180.00
- AVG Volume (30 Days)
- CISS 75.6K
- ALZN 237.8K
- Earning Date
- CISS 08-21-2025
- ALZN 09-10-2025
- Dividend Yield
- CISS N/A
- ALZN N/A
- EPS Growth
- CISS N/A
- ALZN N/A
- EPS
- CISS N/A
- ALZN N/A
- Revenue
- CISS $38,174,754.00
- ALZN N/A
- Revenue This Year
- CISS N/A
- ALZN $322.64
- Revenue Next Year
- CISS N/A
- ALZN N/A
- P/E Ratio
- CISS N/A
- ALZN N/A
- Revenue Growth
- CISS N/A
- ALZN N/A
- 52 Week Low
- CISS $2.85
- ALZN $2.75
- 52 Week High
- CISS $23.25
- ALZN $135.54
- Technical
- Relative Strength Index (RSI)
- CISS 56.47
- ALZN 55.49
- Support Level
- CISS $3.30
- ALZN $2.95
- Resistance Level
- CISS $3.99
- ALZN $3.60
- Average True Range (ATR)
- CISS 0.20
- ALZN 0.19
- MACD
- CISS 0.05
- ALZN 0.12
- Stochastic Oscillator
- CISS 50.00
- ALZN 85.44
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.